Obecabtagene autoleucel - Autolus
Alternative Names: Anti-CD19 CAR T cell therapy - Autolus; AUCATZYL; AUTO 1; CAT19; CD19 CAR T-cells - Autolus; CD19CAT-41BBZ CAR T-cells - Autolus; Obe-celLatest Information Update: 24 Feb 2025
At a glance
- Originator University College London
- Developer Autolus; University College London
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Precursor B-cell lymphoblastic leukaemia-lymphoma
- Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Phase I Systemic lupus erythematosus
Most Recent Events
- 29 Jan 2025 Autolus Limited initiates expanded access program in Precursor B cell lymphoblastic-leukaemia-lymphoma(NCT06799221)
- 07 Dec 2024 Adverse events data from a phase I/II trial in B-cell acute lymphoblastic leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 07 Dec 2024 Efficacy and adverse events data from a phase-I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)